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A B S T R A C T
Several different mechanisms are implicated in the resistance of lung cancer cells to epidermal growth factor
receptor-tyrosine kinase inhibitors (EGFR-TKIs), and only few have been functionally investigated. Here, using
genetically knocked out EGFR and TKI-resistant lung cancer cells, we show that loss of wild-type EGFR attenuates
cell proliferation, migration and 3D-spheroid formation, whereas loss of mutant EGFR or resistance to TKIs
reinforces those processes. Consistently, disruption of wild-type EGFR leads to suppression of HER2/HER3, while
mutant EGFR ablation or resistance to TKIs increases HER2/HER3 expression, compensating for EGFR loss.
Furthermore, HER2/HER3 nuclear translocation mediates overexpression of cyclin D1, leading to tumor cell
survival and drug resistance. Cyclin D1/CDK4/6 inhibition resensitizes erlotinib-resistant (ER) cells to erlotinib.
Analysis of cyclin D1 expression in patients with non-small cell lung carcinoma (NSCLC) showed that its ex-
pression is negatively associated with overall survival and disease-free survival. Our results provide biological
and mechanistic insights into targeting EGFR and TKI resistance.
1. Introduction
Lung cancer is the leading cause of cancer mortality worldwide. In
2018, more than 2 million new cases and 1.7 million lung cancer-re-
lated deaths were reported [1]. Non-small cell lung carcinoma (NSCLC)
is the main type of lung cancer, accounting for 85% of all lung cancer
cases [2]. Surgery or surgery followed by chemotherapy is the common
choice for patients with resectable lung cancer. For those with ad-
vanced stage cancer, targeted therapy can be used to achieve a longer
progression-free survival [2].
Tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib, and
afatinib, are the commonly used targeted agents for NSCLC patients
with certain EGFR mutations [3,4]. EGFR-TKIs bind to the tyrosine
kinase domain of EGFR, blocking tyrosine kinase activity and down-
stream signaling. Approximately 10% of NSCLC patients from Western
countries and 30% of NSCLC patients from East Asia, harboring EGFR-
activating mutations (exon 19 deletions and L858R point mutation),
could benefit from TKIs treatment [5,6]. However, inevitably, almost
all patients treated with TKIs develop resistance within 9–13 months
after treatment initiation [3,7,8].
Mechanisms of EGFR-TKI resistance in NSCLC are complicated. The
gatekeeper mutation T790M contributes to almost 50% of all acquired
resistance to elortinib and gefitinib. Activation of compensatory sig-
naling pathways, such as c-MET, PI3K/AKT/mTOR, JAK2/STAT3, are
other mechanisms of resistance against TKIs [3,9–11]. Furthermore,
dysregulation of HER family receptors and EGFR nuclear trans-location
are reported as mechanisms of resistance [12]. EGFR nuclear translo-
cation is considered a transcriptional co-activator of several well-known
transcription factors, such as STAT3/5[13,14], E2F1[15] and RNA he-
licase A [16], regulating the expression of many essential genes, in-
cluding cyclin D1. Although the function of nuclear EGFR is relatively
clear, functions of other nuclear HER family receptors, including HER2/
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3/4, remain unknown in NSCLC.
In this study, we aimed to characterize cellular and molecular
changes of HER family receptors upon CRISPR/Cas9-mediated disrup-
tion of EGFR or acquisition of resistance to EGFR-TKIs. We showed that
wild-type EGFR ablation results in a substantial inhibition of cell pro-
liferation and migration, but that disruption of mutant EGFR or ac-
quisition of TKI resistance promoted cell proliferation and migration
resulting in cell survival. Furthermore, we found that upregulation of
HER2 and HER3 mediated cyclin D1 overexpression, contributing to
cell survival and proliferation upon EGFR loss or emergence of TKI-
resistance.
2. Materials and methods
2.1. Cell culture and establishment of EGFR EGFR−/− cell lines by
CRISPR/Cas9
Four lung cancer cell lines (A549, H1299, H1650 and HCC827)
were used in this study. A549 (EGFRwt/wt) was purchased from ATCC.
H1299 (EGFRwt/wt) and H1650 (EGFR19del) were gifts from Dr. Klaas
Kok (Department of Genetics, University Medical Center Groningen).
The HCC827 (EGFR19del) cell line was kindly provided by Dr. Martin
Pool (Department of Medical Oncology, University Medical Center
Groningen). The EGFR−/−cell lines (A549 EGFR−/−, H1299 EGFR−/−
and H1650 EGFR−/−) were generated by CRIPR/Cas9, as described
[17,18]. All cell lines were cultured in Roswell Park Memorial Institute
(RPMI)-1640 (Gibco, Carlsbad, USA) containing 1% (v/v) penicillin G/
streptomycin (Invitrogen, Carlsbad, USA) supplemented with 10% (v/
v) fetal bovine serum (FBS) (Thermo Fisher Scientific, Waltham, USA)
in a humidified incubator at 37 °C with 5% CO2. All human cell lines
have been authenticated using STR (or SNP) profiling within the last
three years. All experiments were performed with mycoplasma-free
cells.
2.2. Anti-tumor agents, antibodies, and other reagents
Erlotinib and afatinib were purchased from Selleckchem (Munich,
Germany). Ribociclib was purchased from LC laboratories (Woburn,
USA). All drugs were dissolved in dimethyl sulfoxide (DMSO) and
stored at −20 °C. EGFR (#1005): sc-03-G antibody (1:1000) and pro-
tein A/G PLUS-Agarose:sc-2003 were purchased from Santa Cruz
Biotechnology, USA. Phospho-EGF Receptor (Tyr1173) (2234), HER2
(#29D8, 1:1000), HER3 (#D22C5, 1:1000), Akt (pan) (#C67E7,
1:1000), Phospho-Akt (Ser473) (#193H12, 1:1000), Erk1/2 (#9102,
1:1000), Phospho-Erk1/2 (Thr202/Tyr204) (#20G11, 1:1000), cyclin
D1 (#2922, 1:1000), β-Actin (#4967, 1:10000), and GAPDH (#D4C6R,
1:10000) antibodies were purchased from cell signaling technology,
Leiden, The Netherlands.
2.3. Establishment of EGFR-TKI resistant cell lines
EGFR-TKI resistant cell lines were established by long-term ex-
posure to erlotinib (3 months). To set up EGFR TKI-resistant cell lines,
HCC827 EGFR19del and H1650 EGFR19del were treated with erlotinib
starting at 50 nM, followed by a stepwise dosage increase every 5 days
up to 20 μM and 50 μM, respectively. The erlotinib-resistant (ER) cell
lines HCC827ER and H1650ER were maintained in 2 μM erlotinib for
long-term culture.
2.4. Cell viability
Cell viability was measured using the MTS assay. Cells were seeded
in flat bottom 96-well plates at a density of 1 × 103 cells per well. After
24 hr, cells were treated with appropriate drugs at different doses for
another 72 hr. Subsequently, CellTiter 96 Aqueous One Solution re-
agent (Promega, Madison, USA) was added to each well, according to
manufacturer’s instruction. Plates were incubated at 37 °C for 1hr. The
optical density (OD) was determined at 490 mm wavelength using a
Synergy H1 plate reader (BioTek, Winooski, USA).
2.5. Cell proliferation
The colony formation assay was used to determine cell proliferation.
Cells were seeded in 6-well plates at a density of 1 × 104 cells per well
and were allowed to grow for 4–5 days. Subsequently, cells were fixed
with 4% (v/v) paraformaldehyde for 20 min at room temperature (RT)
in the dark. After washing with phosphate-buffered saline (PBS), cells
were stained with 0.5% (w/v) crystal violet for 15 min. Then, cells were
washed three times with demineralized water and plates were dried at
room temperature. Crystal violet was eluted by 10% (v/v) acetic acid
and OD was measured at 590 mm wavelength using a Synergy H1 plate
reader.
2.6. Cell migration
To measure lateral migration, cells were seeded in a 6-well plate at a
density of 7 × 105 cell per well. After 24 hr incubation, a wound was
gently scraped using a sterile 200 μl pipette tip. The detached cells were
washed away with PBS. Pictures were taken at 0 hr, 12 hr, 24 hr, 48 hr
using a CK2 inverted microscope (Olympus, Tokyo, Japan). The pic-
tures were analyzed by ImageJ (National Institute of Health, USA).
To measure vertical migration, cells were seeded in the top trans-
well inserts at a density of 1 × 104 cells per insert. The inserts were
gently put onto 24-well plates filled with 750 μl cell culture medium.
Culture medium and remaining cells in the inserts were removed after
24 hr incubation at 37 °C with 5% CO2. The insert membrane was fixed
with 4% (v/v) paraformaldehyde and stained with 0.5% (w/v) crystal
violet. Pictures of migrated cells were randomly taken using a CK2
inverted microscope. Subsequently, crystal violet was eluted with 10%
(v/v) acetic acid and the OD590 value was measured using a Synergy
H1 plate reader.
2.7. Generation of a 3D-spheroid tumor model
To mimic actual tumor microenvironment, a 3D-spheroid tumor
model was constructed, which has been detailed previously [19]. The
U-bottom ultra-low attachment culture plate was used for the genera-
tion of a 3D-spheroid tumor model. Approximately 2 × 103 cells per
well were seeded into U-bottom ultra-low attachment 96-well plates.
Plates were centrifuged at 300g for 5 min to form a preliminary 3D
spheroid tumor. After 5 days of incubation, 3D spheroid tumors were
generated. The pictures were taken under the CKX41 microscope
(Olympus, Tokyo, Japan) controlled by Leica Application Suite soft-
ware. The image data were analyzed by ImageJ.
2.8. RNA isolation, cDNA synthesis and qRT-PCR
Cells were harvested by trypsinization and RNA was isolated using
Maxwell LEV simply RNA Cells/Tissue Kit (Promega, Madison, USA),
according to the company’s protocol. A total of 500 ng RNA was re-
verse-transcribed to cDNA using the Reverse Transcription Kit
(Promega, Madison, USA), according to the manufacturer’s instruction.
The SensiMix SYBR Kit (Bioline, Taunton, USA) was used for qRT-PCR
in a QuantStudio 7 Flex Real-Time PCR System (Thermo Fisher
Scientific, Waltham, USA). Data were analyzed by QuantStudio
Software V1.3 (Thermo Fisher Scientific, Waltham, USA). α-tubulin
mRNA level was determined as an internal reference for data normal-
ization.
2.9. Signaling pathway analysis
Cells were seeded at a density of 3 × 105 cells/well and cultured
B. Liu, et al. Biochemical Pharmacology 178 (2020) 114095
2
without starvation and were treated with different concentration of
erlotinib. After 24 h, cells were harvested for western blot analysis.
2.10. Western blot analysis
Cells were harvested by trypsinization and lysed on ice in RIPA
buffer containing 1× PhosSTOP and protease inhibitor (PI) cocktail
(Roche, Mannheim, Germany) for 20 min. The lysates were sonicated
for 10–20 s to reduce the viscosity. Next, samples were centrifuged at
16,000 RCF, 4 °C for 20 min to remove insoluble residues. Protein
concentration was determined using the BCA Protein Assay Kit (Pierce,
Rockford IL, USA), according to the manufacturer’s instruction. Thirty
micrograms denatured protein of each sample was mixed with SDS
buffer and loaded onto a pre-cast 4–12% NuPAGE Bis-Tris gel
(Invitrogen, USA). Later, proteins were transferred to a polyvinylidene
difluoride (PVDF) membrane. After blocking with 5% (w/v) skimmed
milk in PBST (Phosphate Buffered Saline with Tween 20) at room
temperature for 1 hr, the membrane was incubated overnight at 4 °C
with appropriate primary antibody. Then, the membrane was treated
with HRP-conjugated secondary antibody for 1 hr at RT. After each step
the membrane was washed three times with PBST. Blots were lighted up
with enhanced chemiluminescence (ECL) solution (GE Healthcare,
Amersham, UK). Pictures were captured using a chemi genius II bio-
imaging system.
2.11. Nuclear isolation and co-immunoprecipitation (co-IP)
The nuclear isolation and co-immunoprecipitation (co-IP) assay has
been detailed elsewhere [20,21]. Briefly, 3 × 108 Cells were harvested
under non-denaturing conditions for nuclear isolation, followed by
washing with PBS. Cells were resuspended in 400 μl hypotonic lysis
buffer, 0.01× PBS supplemented with 1× protease inhibitor (Roche,
Basel, Switzerland), and incubated on ice for 20 min. Nuclei were
pelleted by centrifugation at 500g, 4 °C for 5 min. Supernatant con-
tained the non-nuclear fraction and the pellet was the nuclear fraction.
To remove the possible cross-contamination between the non-nuclear
fraction and the nuclear fraction, following steps were employed. For
the non-nuclear fraction, it was re-centrifuged five times at 500g, 4 °C
for 5 min. The re-cleaned supernatant was collected, and the residue
pellet was discarded. For the nuclear fraction, after remove the super-
natant, the pellet was washed five times with 500 µl hypotonic lysis
buffer. The re-cleaned pellet was collected as nuclei.
For co-IP, samples were gently washed three times with clod PBS
containing 0.1% CA-630 and 1× protease inhibitor (PI) to minimize
cytoplasmic contamination. Nuclear protein samples were extracted
using 300 μl RIPA buffer containing 1x PhosSTOP and PI. After 20 min
incubation on ice, samples were sonicated and centrifuged at 16,000
RCF, 4 °C for 20 min. The concentration of non-nuclear and nuclear
protein samples was determined by BCA Protein Assay Kit, according to
the manufacturer’s instruction. Approximately 300 μg of cell lysate at
1–1.5 mg/ml was then pre-cleaned by rotation incubation with 20 μl
50% Protein A/G PLUS-Agarose (Santa Cruz Biotechnology, Texas,
USA) at 4 °C for 60 min. Subsequently, appropriate antibody was added
to pre-cleaned samples, followed by overnight rotation incubation at
4 °C. Next, 30 μl 50% Protein A/G PLUS-Agarose was added to each
sample. The mixtures were incubated at 4 °C for overnight with rota-
tion. The pellets were collected by centrifugation at 1000 g for 3 min at
4 °C and washed five times with 500 μl RIPA buffer. The pellets were
well mixed with 20 μl 4× SDS buffer and denatured by heating at 95 °C
for 10 min. Denatured protein samples were analyzed by western blot.
2.12. Sequential chromatin immunoprecipitation (sequential ChIP)
The sequential ChIP-qPCR has been described elsewhere [22–24].
Cells were grown in a T175 cell culture flask to 90% confluency. Freshly
prepared 11% (v/v) formaldehyde solution was directly added to the
flask at a 1% formaldehyde concentration. The flasks were gently
swirled at room temperature for 20 mins for protein-chromatin cross-
link formation, followed by addition of 2.5 M glycine to each flask to
reach a 0.1 M final concentration. After washing with PBS, cells were
harvested under non-denaturing conditions. To isolate the nuclei, the
cell pellet was resuspended in 900 μl lysis buffer and lysed by pipetting.
Then, cell lysates were washed once with 1 ml ChIP lysis buffer.
Chromatin fragments (100–1000 bp) were obtained using micrococcal
nuclease digestion followed by gel electrophoresis. Thirty percent of the
chromatin solution (unbound sample) was stored at −20 °C and the
remaining 70% of chromatin solution was incubated with appropriate
primary antibody overnight at 4 °C with rotation. Then, 30 μl of 50%
Protein A/G PLUS-Agarose was added. After a 3 hr incubation at 4 °C
with rotation, agarose beads were collected and sequentially washed
three times with 1 ml RIPA buffer and twice with 1 ml TE buffer. The
immune complex was eluted with 10 mM dithiothreitol (DTT) in 75 μl
TE buffer at 37 °C for 30 mins. The eluted immunoprecipitate was di-
luted 20 times with dilution buffer. The second round ChIP was per-
formed as the first round. The re-immunoprecipitation was eluted and
cross-links were removed with elution buffer overnight at 65 °C. The de-
cross-linked chromatin and the unbound sample were sequentially in-
cubated with RNase A (10 mg/ml) for 1 hr at 37 °C, and proteinase K
(20 mg/ml) for 2 hr at 56 °C. Finally, DNA fragments were purified with
QIAquick® PCR purification kit (Qiagen, Hilden, Germany) according to
the manufacturer’s instruction. Primers are listed in Table 2. The qPCR
amplifications have been described elsewhere [24].
2.13. Kaplan-meier survival and correlation analysis of patient data
Data for survival analysis was retrieved from The Cancer Genome
Atlas (TCGA) using a standard processing pipeline. Cumulative disease
free survival of NSCLC (LUAD, LUSC) was analyzed using the Kaplan-
Meier method with log-rank test. Correlation between the expressions
of different genes was calculated using Spearman correlation (non-log
scale) based on Gene Expression Profiling Interactive Analysis (GEPIA)
[25]. A two-sided p-value less than 0.05 was considered statistically
significant.
2.14. Quantification of Western blot
All the western blots are quantified by Image J. The quantification
data are shown in Tables 3A to 3D, 4, 5, 6A to 6E and 7.
2.15. Data analysis
Data were derived from three independent experiments and were
presented as mean ± SD. P-values were determined by GraphPad
Prism software v.6.0.1 using one-way ANOVA with multiple compar-
isons and Tukey’s correction. * P ≤ 0.005, *** p ≤ 0.0005, ****
p ≤ 0.0001.
3. Results
3.1. Establishment of EGFR−/− and EGFR-TKI resistant cell lines
To conduct clinically relevant studies of EGFR-positive lung cancer
Table 1
List of NSCLC cell lines used in this study.
Cell line Lung cancer subtype EGFR status
A549 Adenocarcinoma Wild-type
H1299 Adenocarcinoma Wild-type
H1650 Adenocarcinoma Exon19 del
HCC827 Adenocarcinoma Exon19 del
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cells, we established EGFR−/− and EGFR-TKI resistant cell lines. Four
different NSCLC cell lines (A549, H1299, H1650 and HCC827) with
different genotypes were included in this study (Table 1) [26,27]. The
A549, H1299, H1650 EGFR−/− cell lines were generated by using
CRISPR/Cas9 gene editing technology (Fig. 1A) [17,28]. We cannot
obtain the HCC827 EGFR−/− cell line, which might be due to the high
dependency of EGFR or other possibilities [29].
A549 and H1299 contain wild-type EGFR and are resistant to the
erlotinib (an EGFR-TKI), while H1650 and HCC827 harbor an EGFR
exon 19 deletion, which is the most common EGFR mutation and makes
tumor cells sensitive to TKIs. We established HCC827-ER and H1650-ER
cell lines after long-term exposure to erlotinib (Fig. 1A). For
HCC827ER, IC50 increased dramatically from 0.1 ± 0.18 μM to
47.6 ± 0.17 μM. H1650ER cells were able to grow in high dose
(50 μM) of erlotinib without loss of viability, although the parental cells
had moderate response to erlotinib. Furthermore, we observed an ag-
gressive pattern of hyper-progression when H1650ER cells were treated
with erlotinib (Fig. 1A).
3.2. Wild-type EGFR ablation attenuates cell proliferation, migration and
3D spheroid formation, but disruption of EGFR19del or acquired resistance
accelerates them
To elucidate the effect of EGFR ablation and TKI-resistance on
proliferation and migration of lung cancer cells with different EGFR
mutational statuses, we performed colony formation, trans-well, wound
healing and 3D spheroid tumor formation assays.
In EGFRwt/wt cell lines (A549 and H1299), EGFR ablation sig-
nificantly inhibited cell proliferation, vertical and horizontal migration
and tumor formation (Fig. 1B–E). Cell proliferation of EGFR-KO cells
decreased by 50% compared to the parental cells (Fig. 1B). Similarly,
impaired ability of migration was observed in trans-well and wound
healing assays (Fig. 1C and D). Of note, we did not observe significant
changes in the expression of EMT-related markers after EGFR knockout
in our previous study, indicating that this migration changes might not
be related to EMT [17]. In 3D-spheroid tumor formation assay, original
A549 and H1299 cells formed larger tumors and showed stronger
invasion ability than corresponding EGFR−/− cells (Fig. 1E). In con-
trast, we observed opposite results in EGFR19del and erlotinib-resistant
cells. In H1650 and HCC827, EGFR19del ablation or acquired erlotinib
resistance led to acceleration of cell proliferation, vertical and hor-
izontal migration (Fig. 1B–E). For 3D-spheroid formation ability of
H1650, EGFR19del ablation and acquired erlotinib resistance resulted in
slightly and significant enhancement, respectively. However, both
HCC827 cell lines failed to form 3D-spherid.
3.3. Distinct changes in Phospho-p44/42 MAPK (Erk1/2) and Phospho-
Akt (Ser473) levels upon EGFR knockout and acquired TKI resistance
EGFR status can significantly affect two main downstream path-
ways, i.e. the MAPK/pERK(1/2) and PI3K/AKT. EGFR-activating mu-
tations, overexpression or inhibition can dramatically affect these two
pathways and substantially influence cancer cell growth and survival.
To precisely investigate the effect of different EGFR status on these two
pathways, we performed a panel of western blot to detect changes in
the levels of phospho-Erk and phospho-Akt in different NSCLC cell
lines.
We found significant changes in phospho-Erk and phospho-Akt le-
vels upon EGFR ablation or TKI treatment. Phospho-Akt expression
level was higher in A549 EGFR−/− (Fig. 2A), but downregulated in
H1299 EGFR−/− as compared to parental cells (Fig. 2B). Interestingly,
A549 EGFR−/− showed significant increases in both AKT and phospho-
Akt levels in comparison with A549 EGFRwt/wt. However, the increased
levels of phospho-Akt in A549 EGFR−/− were reduced upon elortinib
treatment (Fig. 2A). Strikingly, phospho-Erk levels significantly in-
creased when we treated A549 EGFR−/− with elortinib (Fig. 2A), which
was not observed in any other cell lines (Fig. 2B–D). Similar to A549,
phospho-Akt levels were upregulated in H1650 EGFR−/− and
HCC827ER, but elortinib treatment restrained phospho-Akt levels
(Fig. 2C and D).
3.4. HER2 and HER3 are upregulated in EGFR19del ablated and/or elortinib
resistant cells, but not in EGFRwt/wt disrupted cells
Dysregulation of HER family receptors can occur in patients with
NSCLC upon TKIs treatment [12]. Precise evaluation of HER family
receptor expression levels upon and during treatment with TKIs can
provide deeper understanding of mechanisms of TKI resistance.
Therefore, we investigated alterations in HER2 and HER3 expression
levels upon EGFR ablation and EGFR-TKI resistance.
In EGFRwt/wt cell lines (A549 and H1299), EGFR disruption resulted
in a slight decrease in HER2 and HER3 levels (Fig. 3A and B). However,
cells with mutant EGFR, i.e. H1650 and HCC827, showed a different
pattern. HER2 and HER3 were dramatically upregulated in H1650
EGFR−/− and H1650-ER cells at both mRNA and protein level com-
pared to the parental cells (Fig. 3A and B). In HCC827-ER cells, only
HER2 protein level was upregulated (Fig. 3B). Although HER3 was
significantly upregulated in HCC827-ER at RNA level, this was not re-
flected at protein level, suggesting that post-transcriptional regulation
mechanisms may be involved.
Table 2








Cyclin D1 F 5′- TATTGCGCTGCTACCGTTGA-3′
R 5′- CCAATAGCAGCAAACAATGTGAAA-3′





Quantification of Western Blot for Fig. 2A.
A549 A549 EGFR−/−
Erlotinib (μM) 0 0.1 1 0 0.1 1
EGFR 1.00 ± 0.01 1.10 ± 0.01 0.97 ± 0.02 N/A N/A N/A
pEGFR N/A N/A N/A N/A N/A N/A
ERK 1.00 ± 0.02 0.94 ± 0.01 0.89 ± 0.01 3.69 ± 0.02 2.45 ± 0.04 4.42 ± 0.09
pERK 1.00 ± 0.04 1.03 ± 0.01 0.99 ± 0.03 2.30 ± 0.07 5.22 ± 0.03 11.45 ± 0.09
AKT 1.00 ± 0.03 1.41 ± 0.04 0.63 ± 0.02 2.98 ± 0.03 0.46 ± 0.01 1.60 ± 0.04
pAKT 1.00 ± 0.01 2.67 ± 0.02 N/A 7.34 ± 0.03 3.03 ± 0.05 8.27 ± 0.20
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In addition, we evaluated pSTAT3 levels, since it is an important
downstream protein of HER family receptors. In EGFRwt/wt cell lines,
pSTAT3 was undetectable (Fig. 3B), while pSTAT3 level was sig-
nificantly increased in HCC827ER compared to HCC827 cells (Fig. 3B).
Together, these results suggest that upregulation of HER2 and HER3
occurs only in mutant EGFR knockout and TKI-resistant NSCLC cell
lines, but not in wild-type EGFR knockout cells.
3.5. Pan-HER family inhibitor, afatinib, suppresses phospho-Akt via
inhibition of HER2 and HER3
HER2 and HER2-containing heterodimers have the strongest kinase
activity compared to other HER family receptors, which makes them an
important therapeutic target in patients with cancer. Afatinib not only
can block EGFR, but also inhibits the tyrosine kinase activity of HER2
and other HER family receptors. Since we showed that HER2 and HER3
were upregulated in EGFR19del disrupted and ER cells, we speculated
that suppression of HER2 and HER3 may further inhibit tyrosine kinase
activity and tumor proliferation. Therefore, we treated H1650 EGFR−/
− and HCC827ER cells with afatinib to block HER2- and HER3-medi-
ated signaling (Fig. 4A and B). We observed a decreased level of
phospho-Akt upon afatinib treatment in H1650 EGFR−/− and HCC827-
ER cells (Fig. 4A and B). However, we did not observe significant in-
hibition of cell proliferation, although the downstream phospho-Akt
signaling was decreased by afatinib. Thus, these results suggest that
overexpression of HER2 and HER3 may play other functions than tyr-
osine kinase activity in H1650 EGFR−/− and HCC827-ER cells.
3.6. HER2 and HER3 are overexpressed in the nuclei of EGFR19del ablated
and ER cells
EGFR nuclear translocation is one of the mechanisms of resistance
to TKI in NSCLC. Whether nuclear translocation of other HER family
receptors is also involved in EGFR-TKIs resistance is unclear. Hence, we
assessed HER2 and HER3 expression levels in non-nuclear and nuclear
fraction in our NSCLC cell line panel. We found that HER2 and HER3
were mainly expressed in the nuclei in all tested NSCLC cell lines
(Fig. 5A–E). We observed that H1299 is with the lowest expression of
HER2 and HER3, which is almost undetectable, indicating HER2 and
HER3 might not have important function in H1299. Ablation of EGFRwt/
wt influenced neither HER2 and HER3 expression, nor their nuclear-
membrane distribution in A549 cells (Fig. 5A). Similarly, we did not
observe significant changes of HER2 and HER3 in H1299 EGFRwt/wt and
EGFR−/− cells due to the relatively low expression of protein (Fig. 5A).
Interestingly, HER2 and HER3 were both significantly overexpressed in
the nuclei of EGFR19del disrupted and ER cells compared to the parental
cells H1650 and HCC827 (Fig. 5C–E). This is consistent with the in-
efficacy effects of afatinib because it is more difficult and less efficacy
for the inhibitor to target nuclear HER2 and HER3.
3.7. Transcriptional complex of HER2/HER3/pSTAT3 increases in nuclei,
enriches in the cyclin D1 promoter region and reinforces cyclin D1
expression in EGFR19del ablated and ER cell lines
HER2/HER3/Stat3 can form a transcriptional complex and stimu-
late cyclin D1 expression in breast cancer [22,23]. However, this me-
chanism has not yet been confirmed in lung cancer. Therefore, we
performed co-immunoprecipitation assays to explore this mechanism.
Our results showed that in EGFRwt/wt cell lines, EGFR deletion did not
influence HER2/HER3/pSTAT3 heterotrimer formation in the nucleus
(Fig. 6A and B). However, in EGFR-mutant cell lines, EGFR ablation or
ER led to HER2/HER3/pSTAT3 nuclear enrichment (Fig. 6C and D).
In the next step, we performed sequential ChIP assay to detect the
interactions between HER2/HER3/pSTAT3 and the cyclin D1 (CCND1)
promoter. We found that HER2/HER3 complex bound more to the
CCND1 promoter in HCC827ER and H1650 EGFR−/− cells than in
original cell lines (Fig. 7A). Conversely, less binding was observed in
EGFRwt/wt ablated cells than in parental cell lines (Fig. 7A). Conse-
quently, higher cyclin D1 mRNA levels were observed in EGFR19del
disrupted and ER cells compared to both parental and wild-type EGFR
cells (Fig. 7B). Furthermore, western blotting showed that EGFRwt/wt
ablation downregulated cyclin D1, while disruption of EGFR19del or
erlotinib resistance increased its expression (Fig. 7C). Collectively, de-
letion of EGFR reduced affinity of HER2/HER3 complex to cyclin D1
promoter, decreased cyclin D1 expression in EGFRwt/wt cells, but re-
inforced it in cells with mutant EGFR.
3.8. Ribociclib resensitizes cells to erlotinib
Although no drug is available to directly and specifically inhibit
cyclin D1, an inhibitor of cyclin D1/CDK4/6 (ribociclib) has been ap-
proved by FDA in March 2017 for breast cancer treatment. We asked
Table 3B
Quantification of Western Blot for Fig. 2B.
H1299 H1299 EGFR-/-
Erlotinib (μM) 0 0.1 1 0 0.1 1
EGFR 1.00 ± 0.01 0.86 ± 0.01 1.10 ± 0.01 N/A N/A N/A
pEGFR N/A N/A N/A N/A N/A N/A
ERK 1.00 ± 0.05 0.98 ± 0.03 1.37 ± 0.03 1.59 ± 0.03 1.66 ± 0.03 1.69 ± 0.03
pERK 1.00 ± 0.04 0.78 ± 0.03 0.66 ± 0.03 0.92 ± 0.02 1.45 ± 0.02 1.16 ± 0.03
AKT 1.00 ± 0.01 1.42 ± 0.02 1.42 ± 0.01 0.82 ± 0.01 1.48 ± 0.01 0.64 ± 0.01
pAKT 1.00 ± 0.01 0.53 ± 0.01 0.53 ± 0.01 0.39 ± 0.01 0.46 ± 0.01 0.54 ± 0.01
Table 3C
Quantification of Western Blot for Fig. 2C.
H1650 H1650 EGFR−/−
Erlotinib (μM) 0 0.1 1 0 0.1 1
EGFR 1.00 ± 0.01 1.37 ± 0.01 1.15 ± 0.01 N/A N/A N/A
pEGFR 1.00 ± 0.09 0.68 ± 0.05 0.14 ± 0.03 N/A N/A N/A
ERK 1.00 ± 0.01 1.29 ± 0.01 0.99 ± 0.01 0.93 ± 0.01 1.11 ± 0.01 1.00 ± 0.02
pERK 1.00 ± 0.02 0.27 ± 0.03 0.23 ± 0.02 0.52 ± 0.02 0.59 ± 0.03 0.73 ± 0.02
AKT 1.00 ± 0.10 0.84 ± 0.05 0.72 ± 0.05 0.92 ± 0.05 0.60 ± 0.10 0.97 ± 0.07
pAKT 1.00 ± 0.01 1.00 ± 0.01 0.87 ± 0.01 1.90 ± 0.01 0.94 ± 0.01 1.63 ± 0.06
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whether ribociclib can resensitize ER cells to erlotinib treatment. We
treated EGFR19del cells (H1650ER and HCC827ER) with either erlotinib
or ribociclib or combinations thereof. We observed a significant com-
binatorial effect of ribociclib and elortinib in H1650ER and HCC827ER
cells colony formation (Fig. 8A and B).
To mimic in vivo tumor growth, we further treated H1650ER and
HCC827ER cells using a 3D spheroid model. Consistently, a significant
combinatorial effect of ribociclib and elortinib was observed in
H1650ER 3D-spheroid tumor (Fig. 8C), whereas HCC827ER cells are
not able to form 3D spheroids with treatment.
3.9. High expression of CCND1 is correlated with lower overall survival and
disease-free survival rates in patients with lung cancer
To validate the clinical relevance of our results, we analyzed gene
expression data from patients with lung cancer retrieved from The
Cancer Genome Atlas (TCGA) database. Based on Kaplan-Meier survival
analysis, NSCLC patients with higher cyclin D1 had a significantly lower
overall survival (OS) and disease-free survival rates (DFS) (Fig. 9A). The
median DFS and median OS were significantly shorter in patients with
higher CCND1 expression than those with lower gene expression (2.58
vs 3.55 years, p = 0.013; 3.52 vs 5.16 years, p = 0.038).
Furthermore, there was a significant positive correlation between
HER2 and cyclin D1 expression (Fig. 9 B), which was stronger than
EGFR/ cyclin D1 or HER3/cyclin D1 correlation.
Taken together, these results suggest that cyclin D1 may be a pro-
mising therapeutic target for patients with NSCLC.
4. Discussion
Epidermal growth factor receptor is a key therapeutic target for
patients with Non-Small Cell Lung Cancer. Although the majority of
patients with NSCLC harboring EGFR activating mutations benefit from
EGFR-TKI treatment, acquired resistance inevitably arises. Extensive
efforts have led us to the identification of several resistance mechan-
isms, including secondary and tertiary mutations, alternative pathway
activation, cMET amplification, HER2 amplification, EGFR nuclear
trans-localization, oncogenic lncRNA regulation, and tumor micro-
environment alterations [3,8,30,31]. The underlying mechanisms of
EGFR-TKI resistance are not fully understood, mainly due to lack of
approaches for complete elimination of EGFR in cells. Although EGFR
nuclear translocation is one of the resistance mechanisms, whether
Table 3D
Quantification of Western Blot for Fig. 2D.
HCC827 HCC827-ER
Erlotinib (μM) 0 0.1 1 0 0.1 1
EGFR 1.00 ± 0.02 0.60 ± 0.01 0.61 ± 0.01 0.43 ± 0.01 0.40 ± 0.01 0.52 ± 0.01
pEGFR 1.00 ± 0.01 0.17 ± 0.01 0.07 ± 0.01 0.07 ± 0.01 0.06 ± 0.01 0.06 ± 0.01
ERK 1.00 ± 0.01 0.68 ± 0.01 0.95 ± 0.01 0.74 ± 0.01 1.01 ± 0.01 0.99 ± 0.01
pERK 1.00 ± 0.01 0.66 ± 0.01 0.32 ± 0.01 1.05 ± 0.01 1.31 ± 0.01 1.0 ± 0.01
AKT 1.00 ± 0.01 1.19 ± 0.01 1.15 ± 0.01 0.98 ± 0.01 1.29 ± 0.01 1.78 ± 0.03
pAKT 1.00 ± 0.03 0.89 ± 0.06 3.33 ± 0.06 6.45 ± 0.15 7.82 ± 0.12 2.67 ± 0.15
Table 4
Quantification of Western Blot for Fig. 3.
A549 H1299 HCC827 H1650 H1650
EGFRwt/wt EGFR−/− EGFRwt/wt EGFR−/− EGFRwt/wt EGFR−/− EGFRwt/wt EGFR−/− EGFRwt/wt ER
EGFR 1.00 0 1.00 0 1.00 0.72 ± 0.01 1.00 0 N/A N/A
HER2 1.00 ± 0.01 1.08 ± 0.01 1.00 ± 0.01 0.88 ± 0.01 1.00 ± 0.01 1.27 ± 0.02 1.00 ± 0.01 1.35 ± 0.01 1.00 ± 0.01 2.4 ± 0.04
HER3 1.00 ± 0.01 1.18 ± 0.02 1.00 ± 0.01 0.62 ± 0.01 1.00 ± 0.02 0.95 ± 0.02 1.00 ± 0.02 1.02 ± 0.01 1.00 ± 0.01 1.88 ± 0.03
pSTAT3 N/A N/A N/A N/A 1.00 ± 0.14 12.15 ± 0.27 1.00 ± 0.01 0.38 ± 0.01 1.00 ± 0.03 0.91 ± 0.03
Table 5
Quantification of Western Blot for Fig. 4.
H1650 EGFR−/− HCC827-ER
Afatinib (μM) 0 0.1 0 0.1
ERK 1.00 ± 0.01 1.19 ± 0.01 1.00 ± 0.01 1.21 ± 0.01
pERK 1.00 ± 0.02 0.96 ± 0.01 1.00 ± 0.05 0.91 ± 0.06
AKT 1.00 ± 0.06 0.81 ± 0.10 1.00 ± 0.06 0.97 ± 0.04
pAKT 1.00 ± 0.01 0.34 ± 0.01 1.00 ± 0.02 0.28 ± 0.01
Table 6A
Quantification of Western Blot for Fig. 5A.
A549
Non-Nuclear Nuclear
EGFRwt/wt EGFR−/− EGFRwt/wt EGFR−/−
HER2 1.00 ± 0.14 1.16 ± 0.12 1.00 ± 0.01 0.97 ± 0.01
HER3 1.00 ± 0.0.01 1.55 ± 0.01 1.00 ± 0.01 0.99 ± 0.01
Table 6B
Quantification of Western Blot for Fig. 5B.
H1299
Non-Nuclear Nuclear
EGFRwt/wt EGFR−/− EGFRwt/wt EGFR−/−
HER2 N/A N/A 1.00 ± 0.0.04 4.88 ± 0.05
HER3 N/A N/A 1.00 ± 0.2 0.13 ± 0.01
Table 6C
Quantification of Western Blot for Fig. 5C.
H1650
Non-Nuclear Nuclear
EGFRwt/wt EGFR−/− EGFRwt/wt EGFR−/−
HER2 1.00 ± 0.20 4.06 ± 0.28 1.00 ± 0.0.03 9.19 ± 0.19
HER3 N/A N/A 1.00 ± 0.06 43.41 ± 0.62
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HER2/3/4 nuclear translocation contributes to TKI resistance remains
largely unknown. Therefore, we aimed to characterize a panel of
EGFR−/−NSCLC cell lines and further to investigate other HER family
receptors upon EGFR loss or acquired resistance. We show that cells
with mutant EGFR behave differently than wild-type cells after EGFR
disruption. We demonstrate that HER2 and HER3 overexpression and
transcriptional activation of cyclin D1 are other resistance mechanisms
to TKIs in NSCLC.
Our results show that wild-type EGFR ablation resulted in a sig-
nificant inhibition of cell proliferation, migration and 3D spheroid
formation, but EGFR19del ablation increased those processes. Wildtype
EGFR plays an essential role in cell growth by a ligand-dependent
mechanism. Therefore, knockout of EGFRwt/wt leading to the down-
regulation of those abilities is not a surprise. Although EGFR exon 19
deletion is an activating mutation that can promote cell growth through
a ligand-independent activation of tyrosine kinase domain [32], dis-
ruption of mutant EGFR in H1650 cell line promoted cell growth and
migration abilities. We indeed observed that the acute inhibition of
EGFR using TKIs in mutant cells resulted in a dramatic suppression of
cell proliferation. However, EGFR19del cell lines with long-term ex-
posure to elortinib (HCC827-ER and H1650-ER) developed an even
stronger proliferative ability and aggressiveness. These data suggest
that EGFR19del knockout may simulate EGFR-TKI resistance. This is in
agreement with the fact that drug resistance may lead to tumor hyper-
progression [33]. A recent study provided a proof-of-concept of ther-
apeutic benefits of EGFR knockout in EGFR-mutant NSCLC [34].
However, our study raises some concerns on the safety of removing
mutant EGFR from tumor cells.
We observed significant changes in the levels of phospho-Erk and
phospho-Akt upon EGFR ablation, inhibition, or acquired resistance.
Firstly, phospho-Akt levels were higher in A549 EGFR−/−, H1650
EGFR−/− and HCC827-ER than in parental cells. Our data suggest that
activation of the PI3K/AKT pathway may be an important compensa-
tion mechanism for tumor cell survival after EGFR loss. In agreement
with our findings, a recent study showed that Akt activation drives
acquired resistance to EGFR-TKI [35]. However, our study further
revealed that activated Akt induced by EGFR ablation can be further
decreased by elortinib treatment. In addition, phospho-Erk level sig-
nificantly increased only in A549 EGFR−/− cells upon elortinib treat-
ment, which might be due to off-target effects of erlotinib. Of note,
A549 is with KRAS driver mutation. It will be of interests to further
investigate whether the ERK signaling pathway was stimulated by
KRAS in A549 EGFR−/− cells after Erlotinib treatment. We observed a
higher basal level of phospho-Erk in the HCC-827 Erlotinib resistant cell
line (HCC-827 ER), and this increased level of HCC827-ER can be at-
tenuated upon Erlotinib treatment, which therefore is different to A549
EGFR−/− cells. This might be partially because Erlotinib can also in-
hibit other HERs, and HCC827 is response to the treatment. Thus, the
underline mechanisms might be diverged in A549 EGFR−/− and
HCC827-ER, which needs to be further investigated.
Our data revealed that HER2 and HER3 were significantly over-
expressed in EGFR19del ablated and ER cells but downregulated in
EGFRwt/wt disrupted cells. Dysregulation of HER family receptors has
been reported in patients treated with EGFR-TKIs and monoclonal an-
tibodies, but the underlying mechanisms are not fully understood [36].
We showed that upregulation of HER family receptors upon TKIs
treatment or EGFR ablation only occurred in EGFR-mutant tumor cells,
which might be of importance in a clinical setting. Moreover, our
findings, to our knowledge for the first time, further revealed a sig-
nificant nuclear overexpression of HER2 and HER3 in NSCLC EGFR19del
ablated or ER cells. Due to lack of an efficient approach for targeting
nuclear protein, these findings may partially explain ineffectiveness of
combination therapies by anti-EGFR and other HER family receptors.
We found a new mechanism of tumor cell survival through HER2/
HER3/STAT3 complex binding and transcriptional activation of cyclin
D1 in EGFR targeting in NSCLC (Fig. 10). Although cyclin D1 over-
expression mediated by cyclinD1/CDK4/6 signaling and HER2/HER3/
STAT3 nuclear translocation has been identified as an important re-
sistance mechanism and therapeutic target in breast cancers
[23,37–39], whether they also occur in lung cancer was unknown.
Firstly, we showed that HER2 and HER3 have nuclear overexpression in
mutant EGFR knockout and ER cell lines, which may compensate for
EGFR loss. Secondly, we observed that HER2, HER3 and pSTAT3 form
more heterotrimers in nuclei upon mutant EGFR ablation and erlotinib
resistance. Thirdly, HER2/3/pSTAT3 complexes were enriched and
bound to cyclin D1 promoter and subsequently activated cyclin D1
expression only after mutant EGFR knockout and erlotinib resistance.
However, we observed an opposite result in cells with wild-type EGFR.
Furthermore, ribociclib was able to resensitize cells to erlotinib. Thus,
our findings demonstrate that cyclin D1 overexpression mediated by
HER2/3 nuclear translocation is a mechanism of TKI resistance in
NSCLC. In addition, cyclin D1 high overexpression is associated with
shorter overall survival and disease-free survival. Cyclin D1 might be a
promising therapeutic target for patients with resistant NSCLC. Con-
comitant inhibition of EGFR and cyclin D1 may result in more promi-
nent outcomes.
In conclusion, our results show a distinct expression pattern of HER
family receptors after EGFR loss in different NSCLC cells and it appears
to be a mechanism of resistance to TKIs in NSCLC. Moreover, inhibition
of wild-type and mutant EGFR showed distinguished impacts on other
HER family receptors as well as tumor survival. In addition, cyclin D1
may be a potential therapeutic target for patients with resistant NSCLC.
Table 6D
Quantification of Western Blot for Fig. 5D.
H1650
Non-Nuclear Nuclear
EGFRwt/wt ER EGFRwt/wt ER
HER2 1.00 ± 0.01 0.42 ± 0.02 1.00 ± 0.01 2.24 ± 0.01
HER3 N/A N/A 1.00 ± 0.01 19.83 ± 0.10
Table 6E
Quantification of Western Blot for Fig. 5E.
HCC827
Non-Nuclear Nuclear
EGFRwt/wt EGFR−/− EGFRwt/wt EGFR−/−
HER2 1.00 ± 0.02 0.32 ± 0.01 1.00 ± 0.01 3.04 ± 0.01
HER3 1.00 ± 0.0.07 0.50 ± 0.03 1.00 ± 0.05 1.82 ± 0.08
Table 7
Quantification of Western Blot for Fig. 6.
A549 H1299 H1650 HCC827
NC EGFR−/− NC EGFR−/− NC EGFR−/− NC ER
HER3 1.00 ± 0.03 0.72 ± 0.01 N/A N/A 1.00 ± 0.05 1.50 ± 0.03 1.00 ± 0.07 2.17 ± 0.03
pSTAT3 1.00 ± 0.04 0.94 ± 0.01 N/A N/A 1.00 ± 0.08 1.44 ± 0.06 1.00 ± 0.01 10.40 ± 0.18
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Fig. 1. Characterization of EGFR loss and erlotinib resistant phenotypes in different NSCLC cell lines. A. Establishment of EGFR knockout and erlotinib-resistant (ER)
NSCLC cell lines B. Cell proliferation determined by colony formation assay. C. Transwell assay to measure vertical migration. D. Wound healing assay to measure
lateral migration. E. 3D-spheroid tumor formation with U-bottom ultra-low attachment culture.
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Fig. 2. Western blot analysis of downstream
pathways after elortinib treatment in EGFR
knockout, erlotinib resistant and original
NSCLC cells. A. Western blot analysis of
A549 EGFRwt/wt and EGFR−/− cells. B.
Western blot analysis of H1299 EGFRwt/wt
and EGFR−/− cells. C. Western blot analysis
of H1650 EGFRdel and EGFR−/− cells. D.
Western blot analysis of HCC827 and
HCC827ER cells.
Fig. 3. Expression levels of HER2 and HER3. A. Relative mRNA expression of HER2 and HER3 as compared to parental cells. B. Western blot analysis of EGFR, HER2,
HER3 and pSTAT3 in different NSCLC cell lines.
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Fig. 4. Effects of afatinib treatment on
MAPK/ERK and PI3K/AKT signaling and
the cell proliferation. A. MAPK/ERK and
PI3K/AKT signaling and cell proliferation
with treatment of afatinib in H1650 and
H1650 EGFR−/−. B. MAPK/ERK and PI3K/
AKT signaling and cell proliferation with
treatment of afatinib in HCC827 and
HCC827 ER.
Fig. 5. Western blot analysis of HER2 and HER3 expression levels in non-nuclear and nuclear fractions of NSCLC cells. A. Western blot analysis of HER2 and HER3
expression levels in non-nuclear and nuclear fractions from A549 and A549 EGFR−/− cells B. Western blot analysis of HER2 and HER3 expression levels in non-
nuclear and nuclear fractions from H1299 and H1299 EGFR−/− cells. C. Western blot analysis of HER2 and HER3 expression levels in non-nuclear and nuclear
fractions from H1650 and H1650 EGFR−/− cells. D. Western blot analysis of HER2 and HER3 expression levels in non-nuclear and nuclear fractions from H1650 and
H1650 ER cells. E. Western blot analysis of HER2 and HER3 expression levels in non-nuclear and nuclear fractions from HCC827 and HCC827 ER cells.
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Fig. 6. Co-Immunoprecipitation (Co-IP) analysis of
HER2/3/pSTAT3 heterotrimer in NSCLC nuclei. A.
Co-Immunoprecipitation analysis of HER2/3/
pSTAT3 heterotrimer from A549 and A549 EGFR−/
− nuclear lysates. B. Co-Immunoprecipitation ana-
lysis of HER2/3/pSTAT3 heterotrimer from H1299
and H1299 EGFR−/− nuclear lysates. C. Co-
Immunoprecipitation analysis of HER2/3/pSTAT3
heterotrimer from H1650 and H1650 EGFR−/−
nuclear lysates. D. Co-Immunoprecipitation analysis
of HER2/3/pSTAT3 heterotrimer from HCC827 and
HCC827ER nuclear lysates.
Fig. 7. HER2 and HER3 complex binding to cyclin D1 promoter and cyclin D1 expression levels upon EGFR loss or erlotinib resistance in different NSCLC cell lines. A.
Enrichments of HER2 and HER3 complex binding to cyclin D1 promoter detected by sequential ChIP and qRT-PCR. Chromatins were first immunoprecipitated with
HER2 antibody and were re-immunoprecipitated using HER3 antibody. Primer set for sequential ChIP was designed to amplify the fragment of cyclin D1 promoter
including the binding site of HER2/3/pSTAT3 complex. B. Relative mRNA expression of cyclin D1. C. Western blot and its quantification analysis of cyclin D1
expression in different NSCLC cell lines.
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Fig. 8. Effects of the treatment with Elortinib and/or Ribociclib in H1650ER and HCC827ER cells. A. erlotinib or ribociclib or the combinations thereof for
HCC827ER. B. erlotinib or ribociclib or the combinations thereof for H1650ER. C. erlotinib or ribociclib or the combinations thereof for H1650ER-3D spheroid tumor.
Fig. 9. Gene expression data analysis from patients with lung cancer. A. CCND1 high expression is associated with a poor prognosis of lung cancer patients.
Kaplan–Meier survival curve of disease-free survival (DFS) and overall survival (OS) in NSCLC patients with high CCND1 expression and low CCND1 expression. B.
Correlation between CCND1 and Her family receptors. The correlation between CCND1 and Her family receptors based on TCGA data in GEPIA. TPM: Transcripts Per
Kilobase of exon model per Million mapped reads.
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